Live Chat ×
Skip to main content

Treatment Challenges in Convulsive Status Epilepticus: An Evidence-based Approach - Ask The Expert 2016 Webinar Recording

This item is expired.

Provided by the American Epilepsy Society
Recording Date: March 8, 2016
Launch Date: March 21, 2016
Expiration Date: March 21, 2019

Needs Statement

The article "Evidence-Based Guideline: Treatment of Convulsive Status Epilepticus in Children and Adults: Report of the Guideline Committee of the American Epilepsy Society" was published in the January-February 2016 issue of Epilepsy Currents. This webinar was an opportunity to discuss the guideline and treatment algorithm with one of the article's authors, Dr. Tracy Glauser.
The optimal initial pharmacologic treatment for convulsive status epilepticus is unclear. An analysis of the efficacy, tolerability and safety data for anticonvulsant treatment of children and adults with convulsive status epilepticus was used to develop an evidence-based treatment algorithm. Additionally, a standardized literature search was conducted and the evidence synthesized. Despite the paucity of well-designed randomized controlled trials, the authors were able to reach practical conclusions based on the available evidence and develop an integrated treatment algorithm for the treatment of convulsive status epilepticus across the age spectrum (infants through adults).

Target Audience

Epileptologists, neurologists, professionals in epilepsy care, and other interested healthcare professionals

Learning Objectives

Following participation in the activity, the learner should be able to:
  • Review and discuss the evidence-based clinical practice guideline on treatment of convulsive status epilepticus in adults and in children;
  • Appropriately employ the algorithm on the treatment of convulsive status epilepticus;
  • Discuss the need for well-designed research to answer the clinically relevant questions identified in this evidence-based review and guideline development process.


The American Epilepsy Society is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation

The American Epilepsy Society designates this enduring material activity for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
International Credits: The American Medical Association has determined that non-US. licensed physicians who participate in this CME activity are eligible for AMA PRA Category 1 Credits™.
Physician Assistants: AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credits™ from organizations accredited by ACCME or a recognized state medical society. Physician assistants may receive a maximum of 0.5 hours of Category 1 credit for completing this program.

Instructions for Participation to Earn CME Credit

  • Read the needs statement, target audience, learning objectives, and planner/faculty disclosures.
  • View/read the educational content online or printed out.
  • Complete the evaluation

Policy on Commercial Support and Conflict of Interest

As an ACCME-accredited provider the American Epilepsy Society must ensure 100% compliance with the ACCME Standards for Commercial Support: Standards to Ensure Independence in CME Activities. The American Epilepsy Society has implemented mechanisms, prior to the planning and implementation of this CME activity, to identify and resolve conflicts of interest for all individuals in a position to control content of this CME activity

Disclosure of Unlabeled/Unapproved Uses

This educational activity may include references to the use of products for indications not approved by the FDA. Faculty have agreed to disclose intent to discuss any off-label, experimental, or investigational use of drugs, devices, or equipment or devices in their presentations. Furthermore, faculty have attested that all. All the recommendations involving clinical medicine they make in this activity will be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients; and, all scientific research referred to, reported, or used in their presentation in support or justification of a patient care recommendation will conform to the generally accepted standards of experimental design, data collection and analysis. Faculty opinions expressed with regard to unapproved, investigational or experimental uses of products are solely those of the faculty and are not endorsed by the American Epilepsy Society.


This CME activity is for educational purposes only and does not constitute the opinion or endorsement of, or promotion by, the American Epilepsy Society. Reasonable efforts have been taken to present educational subject matter in a balanced, unbiased fashion, and in compliance with regulatory requirements. However, each activity participant must always use his or her own personal and professional judgment when considering further application of this information, particularly as it may relate to patient diagnostic or treatment decisions including, without limitation, FDA-approved uses and any off-label, investigational and/or experimental uses.

Faculty, Planning Committee, Reviewers’ Disclosures of Financial Relationships

In accordance with the ACCME Standards for Commercial Support, the AES requires that any person who is in a position to control content of a CME activity must disclose all relevant financial relationships that they have with a commercial interest. The following individuals contributed to this activity’s content.


Dennis Dlugos, MD, Childrens Hospital of Philadelphia, Philadelphia, PA
Dr. Dlugos has indicated he has no financial relationships to disclose relevant to this activity.
Tracy Glauser, MD, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio
Disclosure: Dr. Glauser has disclosed the following relevant financial relationships: Royalties, Intellectual Property Rights, Ownership interest from AssureX Health, Consulting Fee from Supernus, Scientific Advisory Board member for AssureX Helath, Claritas Genomics, and Expert witness for Eisai.

AES Staff
AES Staff involved in this activity have indicated they have no financial relationships to disclose relevant to this activity.
CME Reviewer
Dennis Dlugos, MD, Childrens Hospital of Philadelphia, Philadelphia, PA
Dr. Dlugos has indicated he has no financial relationships to disclose relevant to this activity.

Resolution of Conflicts of Interest

It is the policy of the American Epilepsy Society to ensure balance, independence, objectivity and scientific rigor. All persons involved in the selection, development and presentation of content are required to disclose any real or apparent conflicts of interest. In accordance with the ACCME Standards for Commercial Support of CME, the AES implemented the mechanisms of prospective peer review of this CME activity, to identify and resolve any conflicts. Additionally, the content of this activity is based on the best available evidence.

Contact Information

For further information on this activity contact the American Epilepsy Society at or call 312.883.3800.

Privacy and Confidentiality

The American Epilepsy Society respects the privacy and confidentiality of users of this CME activity. You may access the privacy statement for this activity here